INNOVATE (VATE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Virtual annual meeting of stockholders scheduled for June 13, 2024, was convened but adjourned due to technical difficulties with the third-party hosting site.
The meeting is rescheduled to June 18, 2024, at 12:00 noon, and will be accessible via live audio webcast.
Voting matters and shareholder proposals
No business was conducted at the originally scheduled meeting due to technical issues; all voting matters are deferred to the reconvened meeting.
Shareholder rights and capital structure
Stockholders retain the right to attend, vote, and submit questions at the rescheduled virtual meeting.
Common stock and preferred stock purchase rights are registered and traded on the New York Stock Exchange under the symbol VATE.
Partial view of Summaries dataset, powered by Quartr API
Latest events from INNOVATE
- Q4 2025 revenue up 61.7% to $382.7M, with strong Infrastructure growth and narrowing net loss.VATE
Q4 202526 Mar 2026 - Q2 net income rose to $14.4M as margins improved and Life Sciences posted record sales.VATE
Q2 20242 Feb 2026 - Q3 revenue dropped 35.5% to $242.2M; growth in Life Sciences and Spectrum, but going concern risk remains.VATE
Q3 202416 Jan 2026 - Revenue declined, but Life Sciences and Spectrum grew; debt reduced and backlog remains strong.VATE
Q4 202425 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and governance after major 2024 changes.VATE
Proxy Filing2 Dec 2025 - Director elections, say-on-pay, and auditor ratification up for vote at June 2025 meeting.VATE
Proxy Filing2 Dec 2025 - Revenue fell 22.7% to $242M, net loss $22M, Life Sciences grew, major debt refinancing completed.VATE
Q2 202523 Nov 2025 - Revenue dropped 13% to $274.2M; backlog and regulatory wins offset high debt risk.VATE
Q1 202515 Nov 2025 - Q3 revenue up 43% to $347.1M, net loss narrowed, and refinancing triggered asset sales.VATE
Q3 202513 Nov 2025